← Leaderboards
Jeffrey L Platt
Mayo Clinic Coll Of Medicine, Rochester
$15,759,960
Attributed
$21,454,938
Total exposure
14
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,769,883 · 15
By mechanism
R01$13,478,689 · 6
P01$9,147,826 · 4
R37$3,880,618 · 1
R21$855,250 · 2
R56$387,500 · 1
R13$20,000 · 1
Top collaborators
- Marilia Isabel Cascalho15 shared
- Ira J. Fox5 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Scott L Nyberg$4,004,143
- Christopher G.a. Mc Gregor$10,138,712
- Marilia Isabel Cascalho$7,150,037
- Larry R Pease$8,572,263
- Gerard Vockley$16,649,608
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneTransplantationAntigensResponseAntibodiesB-LymphocytesTransplant RecipientsCellsPropertyProductionImmunityImmune ResponseBiologicalGraft FunctionChronicMediatingSpecificityAcuteNovel StrategiesHeart TransplantationImmunoglobulinsExhibitsInjuryAvidity
Grant awards (57)
TNFRSF13B polymorphisms and immunity to transplantation$768,714
R01 · FY2025 · AI
TNFRSF13B polymorphisms and immunity to transplantation$764,863
R01 · FY2025 · AI
Donor-specific B cells in Transplantation.$467,791
R01 · FY2025 · AI
Donor-specific B cells in Transplantation$74,813
R01 · FY2024 · AI
TNFRSF13B polymorphisms and immunity to transplantation$33,099
R01 · FY2024 · AI
TNFRSF13B polymorphisms and immunity to transplantation$809,740
R01 · FY2023 · AI
Donor-specific B cells in Transplantation$537,042
R01 · FY2023 · AI
Donor-specific B cells in Transplantation$530,219
R01 · FY2022 · AI
TNRSF13B polymorphisms and the control of innate B cell responses â a double edged sword$195,000
R21 · FY2022 · AI
Donor-specific B cells in Transplantation$550,424
R01 · FY2021 · AI
TNRSF13B polymorphisms and the control of innate B cell responses â a double edged sword$234,000
R21 · FY2021 · AI
Hepatocyte xenografts for treatment of acute liver failure$1,001,746
R01 · FY2020 · AI
Donor-specific B cells in Transplantation$564,899
R01 · FY2020 · AI
Hepatocyte xenografts for treatment of acute liver failure$1,006,195
R01 · FY2019 · AI
Hepatocyte xenografts for treatment of acute liver failure$1,004,804
R01 · FY2018 · AI
Hepatocyte xenografts for treatment of acute liver failure$998,829
R01 · FY2017 · AI
Hepatocyte xenografts for treatment of acute liver failure$1,034,028
R01 · FY2016 · AI
Accommodation in Transplantation$387,500
R56 · FY2016 · AI · contact PI
Enhancing resistance to enteric pathogens$193,750
R21 · FY2016 · AI
Enhancing resistance to enteric pathogens$232,500
R21 · FY2015 · AI
Xenogeneic Natural Antibody Targets-Structure/Function$434,091
R37 · FY2010 · HL · contact PI
Cardiac Transplantation in Infancy$1,324,773
P01 · FY2009 · HL · contact PI
Xenogeneic Natural Antibody Targets-Structure/Function$432,312
R37 · FY2009 · HL · contact PI
T cell responses and cardiac transplantation in infancy$369,216
P01 · FY2009 · HL · contact PI
Laboratory Core$184,392
P01 · FY2009 · HL · contact PI
Cardiac Transplantation in Infancy$1,284,605
P01 · FY2008 · HL · contact PI
Xenogeneic Natural Antibody Targets-Structure/Function$413,539
R37 · FY2008 · HL · contact PI
T cell responses and cardiac transplantation in infancy$357,097
P01 · FY2008 · HL · contact PI
Laboratory Core$178,372
P01 · FY2008 · HL · contact PI
Cardiac Transplantation in Infancy$1,224,656
P01 · FY2007 · HL · contact PI
Xenogeneic Natural Antibody Targets-Structure/Function$406,176
R37 · FY2007 · HL · contact PI
T cell responses and cardiac transplantation in infancy$381,758
P01 · FY2007 · HL · contact PI
Heparan Sulfate-TLR in Health, Injury and Immunity$308,278
R01 · FY2007 · AI · contact PI
Laboratory Core$190,711
P01 · FY2007 · HL · contact PI
Cardiac Transplantation in Infancy$1,233,621
P01 · FY2006 · HL · contact PI
Xenogeneic Natural Antibody Targets-Structure/Function$407,000
R37 · FY2006 · HL · contact PI
T cell responses and cardiac transplantation in infancy$363,564
P01 · FY2006 · HL · contact PI
Heparan Sulfate-TLR in Health, Injury and Immunity$317,485
R01 · FY2006 · AI · contact PI
Laboratory Core$181,640
P01 · FY2006 · HL · contact PI
Cardiac Transplantation in Infancy$1,247,290
P01 · FY2005 · HL
Xenogeneic Natural Antibody Targets-Structure/Function$357,500
R37 · FY2005 · HL
T cell responses and cardiac transplantation in infancy$354,817
P01 · FY2005 · HL
Heparan Sulfate-TLR in Health, Injury and Immunity$325,125
R01 · FY2005 · AI
Laboratory Core$176,504
P01 · FY2005 · HL
Administrative$94,810
P01 · FY2005 · HL
Xenogeneic Natural Antibody Targets-Structure/Function$357,500
R37 · FY2004 · HL
Heparan Sulfate-TLR in Health, Injury and Immunity$325,125
R01 · FY2004 · AI
Xenogeneic Natural Antibody Targets-Structure/Function$357,500
R37 · FY2003 · HL
HEPARAN SULFATE IN CELLULAR IMMUNITY AND GRAFT REJECTION$352,750
R01 · FY2003 · HL
Heparan Sulfate-TLR in Health, Injury and Immunity$325,125
R01 · FY2003 · AI
Conference on Autoimmunity &Tolerance In Renal Disease$20,000
R13 · FY2003 · DK
Xenogeneic Natural Antibody Targets-Structure/Function$357,500
R37 · FY2002 · HL
HEPARAN SULFATE IN CELLULAR IMMUNITY AND GRAFT REJECTION$352,750
R01 · FY2002 · HL
Xenogeneic Natural Antibody Targets-Structure/Function$357,500
R37 · FY2001 · HL
HEPARAN SULFATE IN CELLULAR IMMUNITY AND GRAFT REJECTION$352,750
R01 · FY2001 · HL
HEPARAN SULFATE IN CELLULAR IMMUNITY AND GRAFT REJECTION$352,750
R01 · FY2000 · HL
XENOGENEIC NATURAL ANTIBODY TARGETS--STRUCTURE/FUNCTION$319,345
R01 · FY2000 · HL